<DOC>
	<DOCNO>NCT00923013</DOCNO>
	<brief_summary>Background : Hairy cell leukemia ( HCL ) highly responsive curable cladribine ( CdA ) . HCL respond rituximab , yet standard therapy HCL . Patients CD25-negative variant ( HCLv ) respond poorly initial cladribine respond rituximab anecdotal report . Deoxycytidine kinase phosphorylates cladribine CdATP , incorporate DNA , lead DNA strand break inhibition DNA synthesis . Rituximab anti-CD20 monoclonal antibody induce apoptosis either complement antibody dependent cytotoxicity ( ADCC CDC ) . Patients complete remission ( CR ) cladribine minimal residual disease ( MRD ) immunohistochemistry bone marrow biopsy ( BMBx IHC ) , risk early relapse . Tests HCL MRD blood marrow include flow cytometry ( FACS ) PCR use consensus primer . The sensitive HCL MRD test real-time quantitative PCR use sequence-specific primer ( RQ-PCR ) . In study limited follow-up , MRD detect test RQ-PCR eliminate rituximab cladribine great 90 percent patient , MRD rate cladribine alone unknown . Simultaneous cladribine rituximab might superior inferior delay rituximab detection MRD . Only 4 HCL-specific trial list Cancer.gov : phase II trial cladribine follow 4 week later 8 weekly dos rituximab , phase I-II trial recombinant immunotoxins target CD22 ( BL22 , HA22 ) CD25 ( LMB-2 ) . Objectives : Primary : To determine HCL MRD differ 6 month cladribine without rituximab administer concurrently cladribine . Secondary : - To compare cladribine plus rituximab vs cladribine alone term 1 ) initial MRD-free survival disease-free survival , 2 ) response delay rituximab relapse , determine early rituximab compromise later response . - To determine MRD level tumor marker ( soluble CD25 CD22 ) cladribine and/or rituximab correlate response clinical endpoint . - To determine , use MRD tumor marker data , BMBx avoid . - To compare response MRD 1st 2nd course cladribine . - To evaluate effect cladribine rituximab normal T- B-cells . - To enhance study HCL biology cloning , sequence characterize monoclonal immunoglobulin rearrangement . Eligibility : HCL 0-1 prior course cladribine treatment indicate . Design : Cladribine 0.15 mg/Kg/day time 5 dos 2hr i.v . infusion ( day 1-5 ) Rituximab 375 mg/m2/week time 8 week , randomize half begin day 1 , repeat patient blood-MRD relapse least 6 month cladribine . Also may repeat blood-MRD relapse least 6 month delay rituximab . MRD test use primary objective limit BMBx IHC , blood FACS blood consensus PCR , CLIA certify . Blood MRD relapse define FACS positivity low blood count ( ANC less 1500/microl , Plt le 100,000/microl , Hgb le 11 ) . Stratification : 68 patient 0 62 1 prior course cladribine . Statistics : 80 % power discriminate rate MRD 5 vs 25 % , 10 vs 35 % Non-randomized arm : 20 HCLv begin rituximab cladribine . Accrual Ceiling : 152 patient ( 130 HCL , 2 extra HCL need , 20 HCLv . )</brief_summary>
	<brief_title>Cladribine With Simultaneous Delayed Rituximab Treat Hairy Cell Leukemia</brief_title>
	<detailed_description>Background : Hairy cell leukemia ( HCL ) highly responsive curable cladribine ( CdA ) . HCL respond rituximab , yet standard therapy HCL . Patients CD25-negative variant ( HCLv ) respond poorly initial cladribine respond rituximab anecdotal report . Purine analogs cladribine pentostatin similar efficacy HCL , inhibit DNA synthesis selectively HCL cell . Cladribine effective 1 cycle . Rituximab anti-CD20 monoclonal antibody induce apoptosis either complement antibody dependent cytotoxicity ( ADCC CDC ) . Patients complete remission ( CR ) cladribine minimal residual disease ( MRD ) immunohistochemistry bone marrow biopsy ( BMBx IHC ) , risk early relapse . Tests HCL MRD blood marrow include flow cytometry ( FACS ) PCR use consensus primer . The sensitive HCL MRD test real-time quantitative PCR use sequence-specific primer ( RQ-PCR ) . In study limited follow-up , MRD detect test RQ-PCR eliminate rituximab cladribine &gt; 90 % patient , MRD rate purine analog alone unknown . Simultaneous cladribine rituximab might superior inferior delay rituximab detection MRD . Only 4 HCL-specific trial list Cancer.gov : phase II trial cladribine follow 4 week later 8 weekly dos rituximab , phase I-II trial recombinant immunotoxins target CD22 ( BL22 , HA22 ) CD25 ( LMB-2 ) . Objectives : To determine HCL MRD differ 6 month cladribine without rituximab administer concurrently cladribine . Eligibility : HCL 0-1 prior course cladribine pentostatin treatment indicate . Design : Cladribine 0.15 mg/Kg/day time 5 dos 2hr i.v . infusion ( day 1-5 ) Rituximab 375 mg/m2/week time 8 week , randomize half begin day 1 , repeat patient blood-MRD relapse least 6 month cladribine . Also may repeat blood-MRD relapse least 6 month delay rituximab . MRD test use primary objective limit BMBx IHC , blood FACS blood consensus PCR , CLIA certify . Blood MRD relapse define FACS positivity low blood count ( ANC less 1500/microl , Plt le 100,000/microl , Hgb le 11 ) . Patients FACS-negative blood bone marrow aspirate consider MRD-negative regardless blood count . Stratification : 68 HCL patient 0 62 1 prior course purine analog Statistics : 80 % power discriminate rate MRD 5 vs 25 % , 10 vs 35 % Non-randomized arm : 20 HCLv begin rituximab cladribine . Accrual Ceiling : 152 patient ( 130 HCL , 2 extra HCL need , 20 HCLv . )</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Neoplasm , Residual</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<criteria>INCLUSION CRITERIA : Evidence HCL flow cytometry , review Laboratory Pathology , NCI , include positivity CD19 , CD22 , CD20 , CD11c . BMBx consistent HCL , review Laboratory Pathology , NCI . BMBx may negative HCLv patient increase peripheral blood HCLv cell spleen size . Treatment indicate base demonstration least one follow 4 week time enrollment , less 6 month prior purine analog le 4 week prior treatment , applicable . Neutropenia ( ANC le 1000 cells/microl ) . Anemia ( Hgb less 10g/dL ) . Thrombocytopenia ( Plt less 100,000/microl ) . Absolute lymphocyte count ( ALC ) great 5,000 cells/microL Symptomatic splenomegaly . Enlarging lymph node great 2cm . Repeated infection require oral i.v . antibiotic . Patients eligible blood count within 4 week enrollment consider ineligible subsequent blood count prior enrollment fluctuate become ineligible time enrollment . No prior purine analog therapy except 1 prior course cladribine . No prior rituximab unless HCLv patient . ECOG performance status ( 70 ) 03 . Patients must able understand give informed consent . Women childbearing age men must use birth control type least 12 month last dose therapy . Creatinine le equal 1.5 creatinine clearance great equal 60 ml/ml . Bilirubin le equal 2 unless consistent Gilbert ( total/direct great 5 ) , ALT AST less equal 2.5 time upper limit normal . No therapy ( i.e . chemotherapy , interferon ) 4 week prior study entry , cladribine 6 month prior study entry . Age least 18 Men woman reproductive potential must agree use acceptable method birth control treatment twelve month completion treatment . Subject provide write informed consent EXCLUSION CRITERIA : Presence active untreated infection Uncontrolled coronary disease NYHA class IIIIV heart disease . Known infection HIV . Hepatitis B allow viral load undetectable andif antihepatitis B therapy like Entecavir . Hepatitis C allow viral load undetectable , patient receive curative therapy . Patients document history response cladribine , without 50 % improvement platelet , hemoglobin granulocyte . This exclusion apply HCLv . These patient eligible regardless prior response CDA . Pregnant lactate woman . Presence active 2nd malignancy require treatment . 2nd malignancy low activity require treatment ( i.e . low grade prostate cancer , basal cell squamous cell skin cancer ) constitute exclusion . Inability comply study and/or followup procedure . Presence CNS disease , symptomatic . At Investigator discretion , receipt live vaccine within 4 week prior randomization . Efficacy and/or safety immunization period Bcell depletion adequately study . It recommend patient vaccination record possible requirement review . Per investigator discretion , patient may require vaccination/booster administer least 4 week prior initiation study treatment . Review patient immunization status follow vaccination recommend : tetanus ; diphtheria ; influenza ; pneumococcal polysaccharide ; Varicella ; measles , mumps rubella ( MMR ) ; hepatitis B . Patients consider high risk hepatitis B virus ( HBV ) infection investigator determine immunization indicate complete entire HBV vaccine series least 4 week prior participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>February 7, 2017</verification_date>
	<keyword>Hairy Cell Leukemia</keyword>
	<keyword>Cladribine</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Minimal Residual Disease</keyword>
	<keyword>Leukemia</keyword>
</DOC>